Prosemble is pleased to announce the commencement of the immunogenicity phase of its mouse trials, conducted in partnership with TransCure BioServices, following the successful completion of the safety stage. This new phase will assess immune responses in CD34+ humanised mice, enhanced through cytokine-driven immune cell stimulation. During the initial safety phase, all mice remained in good condition with no weight loss observed. Additionally, no significant anomalies were detected throughout the trial. This advancement marks a critical step forward in Prosemble’s ongoing research efforts.